Developing science,
delivering therapies


Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more


4D pharma completes target enrollment of 30 patients for Part A of its Phase I/II clinical trial of MRx-4DP0004 in patients with partly-controlled asthma. Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patients in the second half of 2021. 4D pharma also announces the voluntary discontinuation of enrollment in the Phase II study of MRx-4DP0004 for the treatment of hospitalized patients with COVID-19 in the UK.
New data demonstrating clinical activity of Live Biotherapeutic Blautix in both IBS-C and IBS-D was presented at Digestive Disease Week (DDW) 2021
4D pharma to Present Additional Data from its completed Phase II Study of Blautix for the Treatment of IBS-C and IBS-D at Digestive Disease Week (DDW) 2021. The Company will host a webcast event on May 25 at 17:00 BST (12:00 EDT) to discuss the additional data and how it relates to the current IBS treatment landscape.